Radiation Therapy and PET-CT aided Radiotherapy planning in Prostate Cancer

Andrea Skanjeti (Lyon)

Prostate cancer is the second commonest male specific cancer, with higher mortality rates in African descent population.

In the following overview of the role of radiation therapy on the management of the disease will be described followed by a special focus on the impact of PET/CT for radiotherapy planning. Based on the most recent publications and on up-to-date international guidelines, this presentation will emphasize the specific role of Choline PET/CT, PSMA PET/CT and other tracers such as Acetate for the optimization of the radiation treatment planning in several different settings such as staging or biochemical relapse.

The role of several PET derived data and the utility of new radiopharmaceuticals as well as the potential impact of PET/MRI will be discussed. Overall, although PET has become an unavoidable technique in prostate cancer, still RCT are necessary to document and to establish its role.